Search

everythinglearnresearchcommunity

for

Search:↓

Akinfenrawr experienced negative side effects from oral finasteride and RU58841, and is seeking alternative hair loss treatments. They discuss various options, including raloxifene, oral dutasteride, liposomal finasteride, Breezula, Pyrilutamide, SM04554, and sulforaphane, but have concerns about efficacy, availability, and cost.

Kintor is starting a phase III trial for KX-826 combined with minoxidil for hair loss. Opinions vary on the potential success of the treatment, with some skepticism expressed.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

A user is considering microneedling to enhance absorption of a prescribed topical hair loss treatment containing Minoxidil, Dutasteride, and Latanoprost, while already taking oral Minoxidil and Dutasteride. They seek advice on the effectiveness and safety of combining these treatments, especially due to the cost and their desire to maximize results.

The conversation discusses using 23andme to determine if someone might respond well to minoxidil for hair loss treatment, and mentions the user's personal experience with micro-needling and minoxidil.

Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.

A user is concerned about starting finasteride due to negative reports and potential side effects. Other users suggest talking to a doctor, considering personal tolerance, and note that side effects are rare.

The user is considering stopping topical minoxidil due to lack of improvement in hair growth and is exploring alternatives like oral minoxidil, topical finasteride, and tretinoin. They are hesitant about oral finasteride and dutasteride, and are open to trying oral minoxidil if available, despite concerns about potential heart-related side effects.

The user is considering trying finasteride again for hair loss despite past side effects like tender nipples and concerns about mental health impacts. They are advised to consult a doctor and consider topical or low-dose finasteride.

The conversation discusses the use of finasteride for hair loss, with OP considering switching to dutasteride due to concerns about effectiveness. Users share experiences and concerns about side effects, including potential impacts on fertility.

Hair transplant recipients are concerned about whether dormant follicles are permanently damaged by incisions, but some believe undamaged follicles could still regrow if a treatment like PP405 is effective. Opinions vary on the impact of transplants on original follicles, with some suggesting treatments like finasteride can help regrow hair.

People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.

Kintor's GT20029, a treatment for hair loss, has completed Phase 1 successfully, showing promise as an androgen receptor degrader that could potentially regrow hair. It is considered more effective than Pyrilutamide, with infrequent dosing and minimal systemic absorption.

The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.

A new hair loss treatment, PP405, is moving from phase 2A to 2B in clinical trials, sparking discussions about its potential to regrow dormant hairs and its impact on existing treatments like Minoxidil and finasteride. Some users express skepticism, while others are hopeful about its future effectiveness.

Results for Amplifica's AMP-303 hair loss treatment study are expected late summer 2024. The study, fully enrolled in Q1 2024, focuses on safety and tolerability.

The user experienced erectile dysfunction from oral finasteride and is considering alternatives like topical high-dose finasteride, RU58841, topical Latanoprost, and oral Minoxidil. Blood tests showed changes in testosterone and DHT levels, and the endocrinologist advised stopping finasteride.

Dr. Toyos is recruiting more participants for a larger trial on hair loss treatments. The discussion mentions Minoxidil, finasteride, and RU58841 as potential treatments.

The user is considering switching from topical minoxidil to a combined oral treatment of finasteride and minoxidil for better consistency but is concerned about potential side effects like shedding, dizziness, and swelling. Another user advises that oral minoxidil should only be used under medical supervision with regular health checks and suggests using reputable brands like Pfizer's Loniten.

PP405 shows promise in hair regrowth, with 31% of participants experiencing over 20% increase in hair density after 8 weeks. Phase 3 trials are expected in 2026, with potential market availability by 2029-2031.

The conversation is about the effectiveness of RU58841 after stopping its use. The user is concerned about losing results if there's a 4-5 day gap before the next bottle arrives.

The conversation discusses enhancing Minoxidil absorption for hair loss treatment using Tretinoin and MSM (Methylsulfonylmethane). The user is seeking sources for Tretinoin and mentions MSM's potential to improve the absorption of topical agents.

A peptide-based delivery system for finasteride shows promise in reducing systemic side effects while maintaining hair growth effectiveness. Combining this with other treatments like minoxidil and RU58841 could enhance results with lower systemic absorption.

PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.

Verteporfin and FAK inhibitors being looked at as potential treatments for hair regeneration, with updates on the unofficial off-label human trial being discussed.

Mixing Dutasteride with MCT oil may improve absorption due to its fat-soluble nature. Users suggest taking it with whole milk or using oil-based capsules for better effectiveness.

A dutasteride simulator predicts that daily 0.5 mg dosing results in higher DHT suppression compared to less frequent dosing. Twice-weekly dutasteride may be as effective as finasteride 5 mg, providing a balance between efficacy and ease of use.

KX-826 initially improves hair growth but declines after 24 weeks, with mild itching as a side effect. Combining it with minoxidil and finasteride may improve results, but long-term effectiveness is uncertain.

People are using lower doses of finasteride than the recommended 1mg daily due to concerns about side effects, cost, and new data suggesting lower doses can be nearly as effective. Some users report stability or slight improvements with lower doses, but the effectiveness compared to 1mg daily is debated.

The user experienced a significant drop in libido and erectile issues after increasing their finasteride dosage, combining oral and topical treatments. They plan to take a break and resume using a lower concentration of topical finasteride to manage side effects.